Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Andrew Dunbar, MD, Min Lu, PhDMD, Mirko Farina, MD, Young Park, BS, Julie Yang, PhD, Dongjoo Kim, PhD, Abdul Karzai, BS, Mohamed E Salama, MD, Jenna Snyder, BS, Aishwarya Krishnan, BS, Richard P. Koche, PhD, Rong Fan, PhD, Ross L. Levine, MD, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138843

Published: 2020

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Mirko Farina, MD, Simona Bernardi, PhD, Nicola Polverelli, Camilla Zanaglio, PhD, Michele Malagola, MD, Federica Re, Federica Cattina, MD PhD, Mariella D'Adda, MD, Giuseppe Rossi, Tatiana Zollner, MD, Andrew Dunbar, MD, Ross L. Levine, MD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 1684.

https://doi.org/10.1182/blood-2019-127451

Published: 2019

Journal Articles

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Blood (2018) 132 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2018-99-110250

Published: 2018

Journal Articles

Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach

Simona Bernardi, PhD, Camilla Zanaglio, PhD, Elif Dereli Eke, PhDStudent, Federica Cattina, MD PhD, Mirko Farina, MD, Stefania Masneri, PhD, Benedetta Rambaldi, MD, Francesca Schieppati, MD, Alessandro Turra, MD, Nicola Polverelli, MD, Enrico Morello, MD, Michele Malagola, MD, Domenico Russo, MD

Blood (2018) 132 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2018-99-109927

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation

Blood (2018) 132 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2018-99-112391

Published: 2018

Journal Articles

A Prospective, Non-Randomized, Multicenter, Phase II Study to Assess Safety and Efficacy of the Infusion of Peripheral Blood Stem Cells Obtained from HLA-Haploidentical Familial Donors (mHaploSCI) after Standard Chemotherapy in Elderly Patients with Acute Myeloid Leukemia at Intermediate or Adverse Risk

Mirko Farina, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Arnalda Lanfranchi, Alessandra Beghin, Enrico Morello, MD, Marta Petullà, Erika Borlenghi, Chiara Cattaneo, MD, Roberto Cairoli, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4464.

https://doi.org/10.1182/blood.V130.Suppl_1.4464.4464

Published: 2017

Journal Articles

Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk

Marco Chiarini, MSc, Viviana Giustini, MSc, Francesco Buccisano, MD, Erika Borlenghi, MD, Mirko Farina, MD, Chiara Cattaneo, MD, Diego Bertoli, MSc, Federico Serana, MD PhD, Alessandro Montanelli, MD, Luisa Imberti, MD, Aldo M. Roccaro, Maria Ilaria Del Principe, Luca Maurillo, MD, PhD, Adriano Venditti, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2697.

https://doi.org/10.1182/blood.V130.Suppl_1.2697.2697

Published: 2017

Journal Articles

Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group

Giuseppe Rossi, MD, Francesca Paoloni, Bruno Fattizzo, MD, Francesca Binda, MD, Mariella D'Adda, MD, Mirko Farina, MD, Cecilia Carbone, MD, Francesco Zaja, MD, Elisa Lucchini, MD, Francesca Romana Mauro, MD, Flavia Salvi, MD, Monia Marchetti, MD, Paola Fazi, Wilma Barcellini, MD

Blood (2017) 130 (Supplement 1): 2199.

https://doi.org/10.1182/blood.V130.Suppl_1.2199.2199

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

Journal Articles

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

Erika Borlenghi, MD, Mirko Farina, MD, Angela Passi, MD, Chiara Pagani, MD, Elisa Cerqui, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marta Petullà, PharmD, Angelo Belotti, MD, Giuseppina Ruggeri, Giuseppe Rossi, MD

Blood (2016) 128 (22): 3993.

https://doi.org/10.1182/blood.V128.22.3993.3993

Published: 2016

Journal Articles

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Erika Borlenghi, MD, Mirko Farina, MD, Marco Chiarini, MSC, Viviana Giustini, MSC, Cinzia Lamorgese, Angela Passi, MD, Enrico Morello, MD, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2016) 128 (22): 2882.

https://doi.org/10.1182/blood.V128.22.2882.2882

Published: 2016

NARROW

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk

Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years

The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only